Informed Consent in Clinical Trials: Rights and Rules
What informed consent means in clinical trials, what the consent document covers, your right to withdraw, and how IRBs protect research participants.
According to ClinicalTrials.gov, the NIH registry maintained by the National Library of Medicine contains more than 500,000 studies in more than 220 countries. The 2007 FDAAA requires registration for most FDA-regulated studies. See our methodology for source documents and refresh cadence.
Consent is written for the condition, not a template
Breast Cancer is the single most-studied condition in the registry, with 1,251 trials; consent for a cancer trial and a healthy-volunteer study cover fundamentally different ground, since each condition's document is built around that condition's own risks and procedures.
- 1,251
- Breast Cancer trials
- 1,096
- Healthy trials
- 1,057
- Obesity trials
- 749
- Prostate Cancer trials
Trial counts are live from the registry mirror used across this site; the consent form's actual content is set per-protocol by the study's own IRB, not by condition alone.
Regulatory framework for clinical trial protections
Three separate regulatory regimes overlap in protecting clinical trial participants. The table below maps each regime to its scope and the participant rights it codifies.
| Regulation | Scope | Core protections |
|---|---|---|
| Common Rule (45 CFR 46) | Federally funded research | IRB review, informed consent, vulnerable populations |
| FDA 21 CFR 50 | Drugs and devices regulated by FDA | Informed consent, exception-from-consent rules |
| HIPAA Privacy Rule | Health information used in research | Authorization for PHI disclosure |
| Declaration of Helsinki | International ethical reference | Risk-benefit, post-trial access |
Informed consent is a continuing conversation, not a one-time signature, you keep the right to ask questions and to withdraw at every stage of a trial.
The Consent Process
Informed consent is not a single event, it is an ongoing process that begins before enrollment and continues throughout your participation. Before you sign anything, the research team must explain the study's purpose, what procedures you will undergo, potential risks and discomforts, potential benefits, alternative treatments available, how your privacy will be protected, and what happens if you are injured during the study.
The consent document itself is typically several pages long and written in plain language. Under 21 CFR 50.27, a copy of the signed form is given to the person signing it. There is no time pressure, you can take the document home, discuss it with family or your personal physician, and ask as many questions as you need before deciding.
Re-consenting for protocol changes
If the study's risk profile changes during the trial (a new adverse event signal, a protocol amendment, a change to the procedures), regulations require re-consent: the research team must inform participants of the change and document continued willingness to participate. Re-consent is not a formality, it is the trial's mechanism for ensuring that the original consent remains current as the science evolves.
Comprehension verification
Best-practice IRBs require the research team to verify participant comprehension before accepting the signature, often through a teach-back conversation in which the participant explains the study's main points back to the team. Comprehension verification is especially important when consent documents run long or when participants face language, literacy, or cognitive barriers.
What the Consent Document Covers
- Study purpose: Why the research is being conducted and what question it aims to answer
- Procedures: What tests, treatments, and visits are involved, including time commitment
- Risks: Known and possible side effects, discomforts, and inconveniences
- Benefits: Potential benefits to you and to medical knowledge (note: there may be no direct benefit to you)
- Alternatives: Other treatments available outside the trial
- Confidentiality: How your health information will be protected and who will have access
- Compensation: Whether you will be paid for participation and whether treatment costs are covered
- Contact information: Who to call with questions or if you experience side effects
- Voluntary participation: Statement that you can withdraw at any time without penalty
Reading a consent form for your condition
A well-studied condition usually means a more mature, better-tested consent document, not a simpler one.
- Look up how many registered trials exist for your specific diagnosis before your first screening call, it tells you how established the research base is. Browse the conditions directory
- Ask what makes this protocol different from earlier trials for the same condition, the consent form should explain what is new. Read the patient-rights guide
- Rare or under-studied conditions often mean fewer prior consent documents to compare against, ask more questions, not fewer. See conditions ranked by trial count
Trial counts measure research volume for a condition, not the safety or quality of any single study.
Your Right to Withdraw
Federal regulations guarantee your right to withdraw from a clinical trial at any time. This right cannot be waived in the consent form. If you decide to leave, the research team should explain any risks associated with stopping treatment abruptly (some medications require tapering rather than immediate cessation) and help transition your care back to your regular physician.
Your decision to withdraw does not affect your access to standard medical care. You cannot be penalized by your health insurer, employer, or healthcare provider for leaving a clinical trial.
How IRBs Protect Participants
Every institution conducting clinical research must have an Institutional Review Board (IRB) - an independent committee composed of scientists, non-scientists, and community members who are not affiliated with the specific research study. The IRB must approve the trial before any participants can be enrolled, and it continues monitoring the trial throughout its duration.
IRBs evaluate the risk-benefit ratio, review consent documents for clarity and completeness, monitor adverse event reports, and can suspend or terminate research that is not being conducted safely. For multi-site trials, a central IRB may oversee the study across all locations.
Special Populations
Additional protections exist for vulnerable populations including children (require parental permission and child assent), pregnant women (additional risk-benefit analysis for the fetus), prisoners (special IRB review), and people with diminished cognitive capacity (legally authorized representative must consent). These protections ensure that research enrollment is truly voluntary and not influenced by the participant's dependent or vulnerable status.
Informed consent is not the signature on the form, it is the conversation the signature documents. Trials that treat consent as a paperwork hurdle fail the regulatory standard even when the form is signed correctly.
Questions to Ask Before Enrolling
- What is the purpose of this study, and why do researchers think the treatment might work?
- What are the possible risks and benefits? What are the odds of each?
- How long will the study last, and how often will I need to visit?
- Will I know which treatment I am receiving (is it blinded)?
- Who pays for my treatment during the trial? What happens if I am injured?
- What happens when the study ends, will I continue to have access to the treatment if it works?
Frequently Asked Questions
What is informed consent in a clinical trial?
Informed consent is a process, not just a signature on a form, through which a potential participant learns about a clinical trial's purpose, procedures, risks, benefits, and alternatives before deciding whether to enroll. The research team must explain everything in understandable language. You have the right to ask questions and take time to decide. Signing the consent form is voluntary and does not waive any legal rights.
Can I leave a clinical trial after I join?
Yes. Participation in any clinical trial is entirely voluntary. You can withdraw at any time, for any reason, without penalty or loss of benefits you are otherwise entitled to. The research team must respect your decision without pressure. If you decide to leave, discuss it with the research team so they can advise on any safety considerations for stopping treatment.
What is an IRB and how does it protect me?
An Institutional Review Board (IRB) is an independent committee that reviews and monitors research involving human subjects. Before any clinical trial can begin, it must be approved by an IRB. The IRB evaluates whether the risks to participants are minimized, the potential benefits justify the risks, informed consent procedures are adequate, and participant selection is equitable. IRBs continue monitoring throughout the trial.